Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
With
Chinese Anti-Cancer Association
It was initiated as an adjuvant chemotherapy trial to test noninferiority of an anthracycline-free short-term regimen (T75C600 x 6 \[TC\] once every 3 weeks) or a short-term regimen (C500E100F500 x 3 once every 3 weeks followed by T100 x 3 every 3 weeks \[CEF-T\]) compared with a standard long-term anthracycline-containing regimen (E90C600 x 4 once every 3 weeks followed by P80 x 12 once every week \[EC-P\]) in HER2-negative breast cancer. Patients were randomly assigned (1:1:1) to each arm after completing the surgical excision of the primary tumor.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, age at diagnosis 18 - 75 years
Histological confirmed unilateral primary invasive carcinoma of the breast
Adequate surgical treatment with complete resection of the tumor (R0) and resection of \> or = 10 axillary nodes or SLN in clinically N0 patients
Node positive disease or node-negative disease with at least one other risk factor (tumor size \> or = 2 cm, grade \> or = II)
HER2-negative disease
No evidence for distant metastasis (M0) after conventional staging
Performance Status ECOG \< or = 1
The patient must be accessible for treatment and follow-up
LVEF\> 50%
Negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients
Leucocytes \> or = 4 x 10\^9/L
platelets \> or = 100 x 10\^9/L
haemoglobin \> or = 9 g/dL
total bilirubin \< or = 1.5 UNL
ASAT (SGOT) and ALAT (SGPT) \< or = 2.5 UNL
creatinine \< 175 mmol/L (2 mg/dL)
You may not be if
1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy）;
2. Has bilateral breast cancer;
3. Has the previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ.
4. Has metastatic (Stage 4) breast cancer;
5. Has any \>T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer);
6. Is pregnant, is breastfeeding women, or women of childbearing age who cannot practice effective contraceptives;
7. Patients participating in other clinical trials at the same time;
8. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension;
9. Has known allergy to taxane and excipients;
10. Has severe or uncontrolled infection.
Clareo Health | Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
